Company profile: Exai Bio
1.1 - Company Overview
Company description
- Provider of AI and machine learning-powered liquid biopsy tests that detect cancer-associated small non-coding RNA biomarkers (oncRNAs) in blood, enabling early detection, tissue-of-origin and subtype identification. Maintains a catalog of over 200,000 unique oncRNAs to support novel RNA-based tests, and partners with biopharma and healthcare to integrate RNA-based liquid biopsy into patient care and personalize treatment.
Products and services
- AI and Machine Learning Analysis: AI-driven interpretation of blood oncRNA patterns to detect cancer types and subtypes, predict tissue-of-origin, and identify early-stage disease in liquid biopsy contexts
- Liquid Biopsy Tests: RNA-based assays that detect cancer-associated small non-coding RNA biomarkers (oncRNAs) abundant in blood of cancer patients and largely absent in healthy individuals, enabling early detection
- OncRNA Catalog: Large-scale compendium of over 200,000 unique oncRNAs from blood samples underpinning development of novel RNA-based tests for early cancer detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exai Bio
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Verastem
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verastem company profile →
Bellwether Bio
HQ: United States
Website
- Description: Provider of novel cell-free DNA-based diagnostic technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bellwether Bio company profile →
ESSA Pharma
HQ: Canada
Website
- Description: Provider of small molecule drugs for cancer treatment, with a focus on advanced prostate cancer, developing therapies that selectively block the N-terminal domain of the androgen receptor, a target required for the growth and survival of most prostate cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ESSA Pharma company profile →
Veraxa Biotech
HQ: Germany
Website
- Description: Provider of ADC development solutions, combining targeted antibody discovery and bioconjugation. Offerings include droplet-based microfluidics for functional antibody screening, site-specific conjugation via proprietary bioorthogonal click chemistry to create uniform, stable ADCs, Positional Intelligence genetic code expansion for precise payload placement, and charged payloads to enhance manufacturing, efficacy, pharmacokinetics, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veraxa Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exai Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exai Bio
2.2 - Growth funds investing in similar companies to Exai Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exai Bio
4.2 - Public trading comparable groups for Exai Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →